VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+3.91%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$245M
AUM Growth
+$31M
(+15%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
12.58%
Top 10 Holdings %
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49
Top Buys
| 1 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
$1.88M |
| 2 |
DocuSign
DOCU
|
$1.49M |
| 3 |
United Airlines
UAL
|
$1.47M |
| 4 |
Fortinet
FTNT
|
$1.35M |
| 5 |
Spotify
SPOT
|
$1.34M |
Top Sells
| 1 |
Applovin
APP
|
$1.45M |
| 2 |
Expedia Group
EXPE
|
$1.04M |
| 3 |
KKR & Co
KKR
|
$976K |
| 4 |
CME Group
CME
|
$974K |
| 5 |
Corpay
CPAY
|
$948K |
Sector Composition
| 1 | Financials | 29.48% |
| 2 | Technology | 14.86% |
| 3 | Healthcare | 14.81% |
| 4 | Industrials | 11.61% |
| 5 | Consumer Discretionary | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MBX
426
MBX Biosciences, Inc. Common Stock
MBX
$388M
| $63.9K | 0.03% |
+3,468
| New | +$63.9K |
|
427
Kura Oncology
KURA
$713M
| $63.9K | 0.03% |
7,336
+3,061
| +72% | +$26.7K |
|
428
Immunovant
IMVT
$2.99B
| $63.8K | 0.03% |
2,577
-885
| -26% | -$21.9K |
|
429
Stoke Therapeutics
STOK
$1.13B
| $63.6K | 0.03% |
5,770
+514
| +10% | +$5.67K |
|
430
Wave Life Sciences
WVE
$1.32B
| $63.5K | 0.03% |
5,133
-9,089
| -64% | -$112K |
|
431
Monte Rosa Therapeutics
GLUE
$305M
| $63.3K | 0.03% |
+9,126
| New | +$63.3K |
|
432
Cartesian Therapeutics
RNAC
$277M
| $63.3K | 0.03% |
+3,533
| New | +$63.3K |
|
|
SLRN
433
DELISTED
ACELYRIN
SLRN
| $63.1K | 0.03% |
20,083
-1,055
| -5% | -$3.31K |
|
434
Regenxbio
RGNX
$490M
| $63K | 0.03% |
8,153
+1,110
| +16% | +$8.58K |
|
435
Beam Therapeutics
BEAM
$2.11B
| $62.8K | 0.03% |
2,534
-1,119
| -31% | -$27.8K |
|
436
AnaptysBio
ANAB
$613M
| $62.7K | 0.03% |
4,733
+936
| +25% | +$12.4K |
|
|
AUTL
437
Autolus Therapeutics
AUTL
$389M
| $62.1K | 0.03% |
26,429
+6,081
| +30% | +$14.3K |
|
438
Janux Therapeutics
JANX
$1.44B
| $61.9K | 0.03% |
1,156
-1,022
| -47% | -$54.7K |
|
439
Denali Therapeutics
DNLI
$2.26B
| $61.7K | 0.03% |
3,029
-1,135
| -27% | -$23.1K |
|
440
Arcus Biosciences
RCUS
$1.3B
| $61.7K | 0.03% |
4,143
-1,281
| -24% | -$19.1K |
|
441
Olema Pharmaceuticals
OLMA
$570M
| $61.7K | 0.03% |
10,579
+3,185
| +43% | +$18.6K |
|
442
Relay Therapeutics
RLAY
$710M
| $61.3K | 0.03% |
14,873
+3,092
| +26% | +$12.7K |
|
443
Avidity Biosciences
RNA
$6.48B
| $61.2K | 0.03% |
2,106
-199
| -9% | -$5.79K |
|
444
Intellia Therapeutics
NTLA
$1.29B
| $61.1K | 0.03% |
5,242
+1,692
| +48% | +$19.7K |
|
445
Keros Therapeutics
KROS
$633M
| $61.1K | 0.02% |
3,857
+1,998
| +107% | +$31.6K |
|
|
CMPS
446
Compass Pathways
CMPS
$493M
| $60.9K | 0.02% |
16,121
+2,840
| +21% | +$10.7K |
|
447
Structure Therapeutics
GPCR
$1.27B
| $60.8K | 0.02% |
2,242
+455
| +25% | +$12.3K |
|
448
Arrowhead Research
ARWR
$4.02B
| $60.4K | 0.02% |
3,211
-267
| -8% | -$5.02K |
|
449
Terns Pharmaceuticals
TERN
$632M
| $59.8K | 0.02% |
10,788
-762
| -7% | -$4.22K |
|
450
Viking Therapeutics
VKTX
$3.03B
| $59.8K | 0.02% |
1,485
-286
| -16% | -$11.5K |
|